1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Pfizer Doesn’t Like Crossover Design For Placebo Patients In COVID-19 Vaccine Trial

 
• By Derrick Gingery

Only vaccinating the placebo group would be much easier once the US FDA grants an EUA for its coronavirus vaccine, Pfizer says.

A crossover design could allow for more long-term safety and efficacy follow-up.

A crossover design to maintain the placebo controls for its coronavirus vaccine trial may be too complicated and labor-intensive for Pfizer Inc..

The company and partner BioNTech SE, have requested an emergency use authorization to use the vaccine in adults age...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers